| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System |
Recent Updates
Recently added Catalysts
NewAmsterdam Pharma Company N.V.$35.26
-0.66 (-1.84%)
B 61Pipeline Score Fair Value Pharma · Commercial
Market Cap
4.14 B
EPS
-1.80
P/E Ratio
-
Value Trade
54.47 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.04 M
R&D Expenses
38.01 M
Operating CF
-30.60 M
Total Assets
732.64 M
Total Liabilities
67.42 M
Equity
665.22 M
D/E Ratio
12,345
-3.25 %
Week
7.72 %
1 Month
3.08 %
3 Month
-5.87 %
6 Month
265.36 %
5 Year
229.67 %
All Time
Cash Data
Cash Position
636.11 M
Monthly Burn
10.20 M
Runway
60.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
564.26 K
52 Week Range
16.79 - 42.21
% held by Insiders
31.51 %
% held by Institutions
72.55 %
Enterprise Value
3.51 B
Total Shares
116.97 M
Short %
14.61 %
Float Shares
62.23 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NewAmsterdam Pharma Company N.V.
227Total events
8Upcoming
53Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 8
Jul 13, 2026
T2Oral Presentation
Oral presentation at AAIC 2026: Predictors of P-tau217 in Cardiovascular Patients: Insights from the Broadway Trial
Jul 14, 2026
T3Poster Presentation
Poster presentation at AAIC 2026: ApoE4-Dependent Dose Response to CETP Inhibition: A Responder Analysis Informing Alzheimer’s Prevention Trial Enrichment Strategies
2026
T2Runway Guidance Update
Cash runway guidance: existing cash expected to fund operations through 2026
Event history 219
Q3 2026
◆EU ApprovalObicetrapibApprovedEx-US Regulatory
Decisions on regulatory approval from EMA for obicetrapib and obicetrapib/ezetimibe FDC expected in 2H26
cardiovascular diseasesource ↗
Q3 2026
◆Other Regulator MilestoneObicetrapibApprovedEx-US Regulatory
Decisions on regulatory approval from UK and Switzerland for obicetrapib and obicetrapib/ezetimibe FDC expected in 2H26
cardiovascular diseasesource ↗
Jun 12, 2026
◆Poster PresentationObicetrapibApprovedPresentation
CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results From the BROADWAY Trial
hypercholesterolemiasource ↗
Jun 12, 2026
◆Poster PresentationPresentation
Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles
hypercholesterolemiasource ↗
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 3, 2026
May 20, 2026
May 12, 2026
May 7, 2026
Apr 13, 2026
◆Oral PresentationPresentation
Virtual fireside chat at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆EU ApprovalObicetrapibApprovedEx-US Regulatory
Approval decision from EMA expected for obicetrapib
cardiovascular diseasesource ↗
Drug Pipeline Intelligence
B61
Pipeline Score $4.3B
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.1x
rNPV / MCap Top 89%
Small Cap (rank 101 of 911)
Percentile RankNewAmsterdam Pharma Company N.V. holds a solid B-grade pipeline (61/100), with $6.7B risk-adjusted pipeline value, led by Obicetrapib in Atherosclerotic Cardiovascular Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| obicetrapib + ezetimibe daily Small molecule | Lipidemia | Phase 3 | NCT07219602 | 53% | $6.7B | RECRUITING | 600 | STALLED | D (23) | Jun 1, 2028 | LOW_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Obicetrapib | cardiometabolic diseases | — | 2026-03-02 | initial 12 month rate is tracking in line with the overall rate observed in the Phase 3 BROADWAY trial Read More | Investor Presentation as of | |
Obicetrapib | cardiometabolic diseases | — | 2026-03-02 | initial 12 month rate is tracking in line with the overall rate observed in the Phase 3 BROADWAY trial Read More | Investor Presentation as of | |
Obicetrapib | cardiometabolic diseases | — | 2026-03-02 | initial 12 month rate is tracking in line with the overall rate observed in the Phase 3 BROADWAY trial Read More | Investor Presentation as of |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NAMS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NAMS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NAMSNewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
NewAmsterdam Pharma announced it will present data on obicetrapib at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will focus on the drug's potential in preventing early Alzheimer's disease, supported by findings from the BROADWAY trial. The company aims to address unmet needs in cardiovascular disease management with this novel therapy.
Read more →NAMSNewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
NewAmsterdam Pharma announced its upcoming presentations at the National Lipid Association 2026 Scientific Sessions, focusing on obicetrapib, a novel oral therapy for hypercholesterolemia. The presentations will cover various aspects of obicetrapib, including safety analyses and its effects on LDL cholesterol. The event will take place from June 11 to 14, 2026, in Chicago.
Read more →NAMSNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma will participate in two major investor conferences in June 2026. CEO Michael Davidson and EVP Matthew Philippe will engage in fireside chats at the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. These events will provide insights into the company's developments in LDL-lowering therapies for cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
NewAmsterdam Pharma will participate in two upcoming investor conferences in May 2026. The BofA Securities Health Care Conference will take place on May 12, followed by the RBCCM Global Healthcare Conference on May 20. Key executives will engage in fireside chats, discussing the company's innovative approaches to treating cardiovascular disease.
Read more →NAMS▲ +12.5%on this news· ran to +25% by day 3shared move
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma reported its first quarter financial results and provided a corporate update, highlighting strong clinical execution with completed enrollment in the REMBRANDT trial and upcoming interim analysis for the PREVAIL trial. The company has a solid cash position of $707.3 million, although it reported a net loss of $48.4 million for the quarter. Regulatory decisions for obicetrapib are anticipated in the second half of 2026.
Read more →NAMS▲ +5%on this news· ran to +23% by day 3shared move
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
NewAmsterdam Pharma has announced the approval of inducement grants for new hires, including share options and restricted stock units. The share options cover 50,400 ordinary shares and will vest over four years, while the restricted stock units cover 15,400 shares and will vest over three years. These grants are part of the company's strategy to enhance its workforce as it develops new therapies for cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma announced the approval of inducement share options and restricted stock units for five new non-executive employees, totaling 50,400 and 15,400 shares, respectively. These grants align with the company's 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $28.43, and will vest over a period of four years, while the restricted stock units will vest over three years. The initiative aims to help attract talent in an industry focused on addressing unmet medical needs in cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
NewAmsterdam Pharma will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. CFO Ian Somaiya and EVP Matthew Philippe will participate in a virtual fireside chat. The company aims to improve treatment for patients with cardiovascular disease through innovative therapies, particularly focusing on LDL-lowering treatments.
Read more →NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
NewAmsterdam Pharma has announced the approval of inducement share options and restricted stock units for new non-executive hires as part of its 2024 Inducement Plan. The share options cover 15,000 ordinary shares and the restricted stock units cover 3,200 shares, both aimed at enhancing employee retention and recruitment. The grants are compliant with Nasdaq Listing Rule 5635(c)(4).
Read more →NAMSNewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NewAmsterdam Pharma announced three presentations at the 2026 American College of Cardiology Annual Scientific Session, focusing on obicetrapib, a novel oral therapy for hypercholesterolemia. The presentations will cover its efficacy in preserving kidney function, safety analysis from Phase III trials, and cardiovascular risks associated with LDL particle levels. The company aims to address unmet needs in LDL-lowering therapies.
Read more →NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
NewAmsterdam Pharma has announced the approval of inducement grants for new hires under Nasdaq Listing Rule 5635(c)(4). The grants include share options for 10,000 ordinary shares and restricted stock units for 2,200 shares, both designed to incentivize employee retention. The share options will vest over four years, while the restricted stock units will vest over three years.
Read more →NAMS▼ -7.4%on this news
Investor Presentation as of
NewAmsterdam Pharma Company N.V. provided an investor presentation detailing its forward-looking statements regarding product development and market opportunities. The presentation highlighted encouraging trial results for Obicetrapib, particularly in reducing LDL-C levels, and the significant unmet medical need in cardiometabolic diseases. However, the company also acknowledged various risks, including uncertainties in clinical trial outcomes and market access challenges. The secured funding indicates a readiness for a potential US commercial launch, aiming to reach the substantial patient population not meeting LDL-C lowering goals.
Read more →NAMSNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NewAmsterdam Pharma will participate in upcoming investor conferences in March 2026. The company is focused on developing oral, non-statin therapies for patients at risk of cardiovascular disease. Their lead product, obicetrapib, is currently being investigated in multiple phase 3 trials. Live webcasts of the presentations will be available on their website.
Read more →NAMSNewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
NewAmsterdam Pharma reported its financial results for 2025, highlighting significant clinical advancements and regulatory progress for its lead product, obicetrapib. The company anticipates approval decisions from European regulators in the second half of 2026 and expects topline data from its RUBENS trial by year-end 2026. With a strong cash position, NewAmsterdam is preparing for potential commercialization in Europe and expanding its U.S. market access capabilities.
Read more →NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
NewAmsterdam Pharma has announced the approval of inducement share options for four new non-executive hires, totaling 217,000 ordinary shares. These options, granted under the 2024 Inducement Plan, have an exercise price of $31.57 and will vest over four years. This move aims to enhance the company's capabilities in developing therapies for cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
NewAmsterdam Pharma will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. CFO Ian Somaiya and EVP Matthew Philippe will participate in a virtual fireside chat. The company focuses on developing oral, non-statin medicines for patients with cardiovascular disease and elevated LDL-C levels.
Read more →NAMSNewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
NewAmsterdam Pharma has outlined its strategic priorities for 2026, highlighting significant achievements in 2025. The company anticipates EMA approval for obicetrapib and its combination with ezetimibe in the second half of 2026. They have also enrolled the first patient in the RUBENS Phase 3 trial and reported a strong financial position with $729 million in cash. The PREVAIL cardiovascular outcomes trial shows promising results in line with previous studies.
Read more →NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026
NewAmsterdam Pharma has announced the grant of inducement share options for 20,000 ordinary shares to a new non-executive hire. This grant, approved by the Compensation Committee, is part of the 2024 Inducement Plan and aligns with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, indicating the company's commitment to long-term employee engagement.
Read more →NAMSNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
NewAmsterdam Pharma has granted inducement share options for 40,000 ordinary shares to two new non-executive hires. This grant, approved by the Compensation Committee, is part of the 2024 Inducement Plan and follows Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, supporting the company's mission to improve therapies for cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
NewAmsterdam Pharma Company N.V. has announced its participation in several investor conferences scheduled for December 2025. Key executives, including the Chief Financial Officer and Chief Executive Officer, will participate in fireside chats to discuss the company's developments in LDL-lowering therapies. The events include the Evercore Healthcare Conference, Citi's Global Healthcare Conference, and the Piper Sandler Healthcare Conference. NewAmsterdam is focused on improving treatment options for patients with cardiovascular disease who are not adequately served by current therapies.
Read more →NAMSNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma announced a corporate update and financial results for Q3 2025, highlighting the acceptance of marketing authorization applications for obicetrapib by the European Medicines Agency. The company reported a strong cash position of $756 million and ongoing clinical trials, including the PREVAIL cardiovascular outcomes trial. CEO Michael Davidson emphasized the commitment to delivering effective therapies for patients with cardiovascular disease.
Read more →NAMS▲ +8.1%on this news
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
NewAmsterdam Pharma will present safety and efficacy data from its Phase 3 trials at the 2025 AHA Scientific Sessions in New Orleans. The presentations will focus on the effects of obicetrapib, a CETP inhibitor, on LDL cholesterol levels. Additionally, company executives will participate in several investor conferences throughout November 2025.
Read more →NAMSNewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
NewAmsterdam Pharma will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025. The presentation will feature Chief Scientific Officer John Kastelein and EVP Matthew Philippe discussing the company's late-stage clinical developments. NewAmsterdam focuses on oral, non-statin therapies for patients with cardiovascular disease who struggle with existing treatments.
Read more →NAMSCorporate Presentation
NewAmsterdam Pharma presented its corporate updates and forward-looking statements regarding its product candidate, Obicetrapib, during their presentation. The drug has shown promising results in clinical trials with significant LDL-C lowering effects and is on track for regulatory submission. The company has successfully secured funding to support its US commercial launch, with a peak sales opportunity estimated to exceed $8 billion. However, there are uncertainties regarding the approval process and the outcomes of the ongoing trials.
Read more →NAMSNewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
NewAmsterdam Pharma Company N.V. will present pooled safety and efficacy data from their pivotal Phase 3 BROADWAY and BROOKLYN trials at the European Society of Cardiology Congress from August 29 to September 1, 2025, in Madrid, Spain. Company management will also participate in three investor conferences shortly after, including the Biopharma Back to School Summit and the Wells Fargo Healthcare Conference. The presentations focus on the efficacy of obicetrapib, an oral LDL-C lowering therapy under investigation, aimed at improving treatment for patients at risk of cardiovascular disease.
Read more →NAMSNewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
NewAmsterdam Pharma announced that the European Medicines Agency has accepted its Marketing Authorization Applications for obicetrapib, both as a monotherapy and in combination with ezetimibe. This follows positive results from pivotal Phase 3 trials demonstrating significant LDL-C reductions. The company aims to provide a new treatment option for patients with hypercholesterolemia.
Read more →NAMS▲ +8.7%on this news
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track &#
NewAmsterdam Pharma provided a corporate update and reported its second quarter financial results, highlighting that its European marketing authorization application is on track for the second half of 2025. The company has reported positive data from the BROADWAY trial, demonstrating obicetrapib's potential in significantly reducing Alzheimer's disease biomarkers. Despite a net loss of $17.4 million, the company maintains a strong cash position of $783.3 million and is confident in its pipeline and the upcoming launch of obicetrapib, if approved. Plans for further trials and commercial readiness are also in place.
Read more →NAMSNewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
NewAmsterdam Pharma presented positive data from the BROADWAY trial at the AAIC 2025, showing that obicetrapib significantly reduced levels of p-tau217, a key Alzheimer's disease biomarker, particularly in ApoE4 carriers. The trial involved 1,515 patients and demonstrated the potential of obicetrapib as a dual therapy for Alzheimer’s and cardiovascular disease. The findings suggest a promising avenue for preventing Alzheimer’s in high-risk populations.
Read more →NAMSNewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
NewAmsterdam Pharma Company N.V. announced plans to present data from its BROADWAY clinical trial on Alzheimer’s disease biomarkers at the upcoming AAIC on July 30, 2025. The presentation will focus on the effects of obicetrapib, a novel oral CETP inhibitor, in a study involving 1727 patients with cardiovascular disease. This event signifies a step forward in research aimed at understanding and treating Alzheimer's disease, with a live webcast planned for further discussion of the findings.
Read more →NAMS▼ -6.1%on this news
Welcome to R&D Day
On June 11, 2025, NewAmsterdam Pharma held an R&D Day to outline their strategic plans and updates regarding ongoing clinical trials, including Alzheimer's and cardiometabolic disease studies. The company reported significant funding secured for a potential US commercial launch and highlighted successful topline results from recent Phase 3 trials. Additionally, they discussed workforce expansion and published research achievements, while cautioning about the uncertainties tied to regulatory approvals and market competition.
Read more →NAMSNewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
NewAmsterdam Pharma announced positive topline results from the BROADWAY clinical trial, demonstrating that obicetrapib significantly reduces Alzheimer's disease biomarkers in patients. The study included a pre-specified sub-study focusing on ApoE4 carriers, revealing statistically significant improvements. The findings suggest a potential preventive strategy for Alzheimer's, with results to be presented at the AAIC conference in July.
Read more →NAMSNewAmsterdam Pharma to Host R&D Day on June 11, 2025
NewAmsterdam Pharma Company N.V. has announced it will host an R&D Day for analysts and investors on June 11, 2025, in New York City. The event will feature key members of the management team and include a live webcast for virtual attendees. NewAmsterdam is focused on developing obicetrapib, a novel CETP inhibitor aimed at patients at risk of cardiovascular disease, with successful Phase 2 and ongoing Phase 3 clinical trials backing its efficacy. The commercialization rights for obicetrapib in Europe have been granted to the Menarini Group.
Read more →NAMSNewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
NewAmsterdam Pharma will present at the 2025 RBCCM Global Healthcare Conference, featuring CFO Ian Somaiya in a fireside chat. The company focuses on developing oral non-statin medications aimed at patients with high levels of LDL-C who struggle with existing therapies. This presentation highlights their ongoing commitment to improving patient care for those at risk of cardiovascular disease. Following the live event, a recording will be available on their website.
Read more →NAMSNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results – EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- B
NewAmsterdam Pharma has provided a corporate update alongside its first quarter financial results for 2025, revealing a strong cash position of $808.5 million. The company anticipates a EMA submission in the second half of 2025, driven by its partner Menarini, while its Phase 3 PREVAIL cardiovascular outcomes trial remains on track. Despite an increased net loss and higher operational expenses, NewAmsterdam reported growth in revenue alongside recent positive clinical results presented at prominent medical conferences. The firm aims to address unmet needs in cardiovascular disease treatment with its innovative LDL-C lowering drug, obicetrapib.
Read more →NAMSNewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 Late Breaking BROA
NewAmsterdam Pharma announced late-breaking data from its pivotal BROADWAY and TANDEM studies, showcasing significant LDL-C reduction with obicetrapib, an oral CETP inhibitor. Data revealed that obicetrapib reduced LDL-C by 50% as an adjunct to statins and showed promising results in reducing cardiovascular events. Presented at the EAS Congress 2025 and published in prominent journals, these findings aim to address unmet needs in cardiovascular disease management. The company envisions obicetrapib as a foundational therapy in treating patients with elevated LDL-C levels.
Read more →NAMSNewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
NewAmsterdam Pharma will present new clinical and preclinical data on obicetrapib at the 93rd EAS Congress, emphasizing its potential as an oral therapy for hypercholesterolemia. The presentations will cover various aspects including LDL-C reduction and efficacy in patients with high cardiovascular risk. The drug aims to provide a safe and effective alternative for those not adequately served by current treatments. These presentations are scheduled for May 4-7, 2025, in Glasgow, UK.
Read more →NAMSNewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma has appointed Adele Gulfo as an independent director to its Board of Directors. Gulfo brings extensive experience in the healthcare sector, notably in global strategy and the commercialization of successful pharmaceutical products. Her appointment is seen as vital as NewAmsterdam gears up for the anticipated launch of obicetrapib, an oral therapy for patients at risk of cardiovascular disease. The company aims to address unmet needs in LDL-C lowering therapies amidst positive readouts from recent clinical trials.
Read more →NAMS▼ -5.9%on this news· ran to -17% by day 3
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NewAmsterdam Pharma is set to participate in the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. Ian Somaiya, the Chief Financial Officer, will join a virtual fireside chat to discuss the company's progress in developing oral, non-statin therapies for cardiovascular disease patients. The company aims to provide effective LDL-lowering treatments for individuals who do not respond well to existing therapies. A live webcast will be available on the company’s investor relations page, with an archived replay to follow.
Read more →NAMS▲ +10.2%on this news
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update -- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented
NewAmsterdam Pharma reported its full year 2024 financial results, highlighting a strong cash position of $834.2 million and positive outcomes from three pivotal Phase 3 trials evaluating obicetrapib, an investigational therapy for cardiovascular disease. The company is preparing for a European Medicines Agency (EMA) submission in the second half of 2025 and plans to share further trial data in 2025. Additionally, NewAmsterdam is focused on launch readiness and has adequate funding to support operations and the anticipated launch of obicetrapib in both the U.S. and Europe.
Read more →NAMSNewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
NewAmsterdam Pharma Company N.V. announced that its CFO Ian Somaiya will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 5, 2025. The company is focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL cholesterol. NewAmsterdam is currently investigating its drug, obicetrapib, in multiple phase 3 trials as a potential LDL-lowering therapy. A live webcast of the discussion will be available on the company's investor relations website.
Read more →NAMSNewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings f
NewAmsterdam Pharma has reported significant achievements in 2024, highlighting positive topline results from three pivotal Phase 3 trials for their lead product, obicetrapib. The company is on track to submit regulatory filings in 2025, bolstered by a strong cash position of $835 million. They plan to present additional clinical data and advance their ongoing cardiovascular outcomes trial. The positive reception of obicetrapib's safety and efficacy paves the way for future commercial opportunities.
Read more →NAMSNewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NewAmsterdam Pharma announced the successful closing of a public offering, raising $479 million by selling 14,667,347 ordinary shares and 4,882,653 pre-funded warrants. The offering was oversubscribed, reflecting strong investor interest, particularly following the full exercise of underwriters' option to purchase additional shares. Proceeds from the offering are expected to bolster the development of their LDL-C lowering therapies, aimed at patients with cardiovascular disease. The offering was conducted under a registration statement that was effective since July 2024.
Read more →NAMSNewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NewAmsterdam Pharma Company N.V. has announced the pricing of an upsized underwritten public offering, amounting to $416.5 million, consisting of 12,117,347 ordinary shares and 4,882,653 pre-funded warrants. The offering is intended to finance the company's development efforts in oral, non-statin medicines aimed at patients with an elevated risk of cardiovascular disease. This strategic financial move could enhance the company's capabilities in advancing its clinical trials and product development pipeline.
Read more →NAMS▲ +41.4%on this newsshared move
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholestero
NewAmsterdam Pharma has released positive topline data from its pivotal Phase 3 BROADWAY trial evaluating obicetrapib for patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. The study achieved its primary endpoint with a statistically significant reduction in LDL-C levels and showed a noteworthy 21% reduction in major adverse cardiovascular events after one year. The treatment was well-tolerated and exhibited a safety profile comparable to placebo, prompting the company to look forward to further discussions with regulatory authorities and upcoming presentations of additional data. Overall, these results highlight obicetrapib's potential as a significant advancement in cardiovascular therapy.
Read more →NAMS▲ +41.4%on this newsshared move
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma announced the commencement of a $300 million public offering of ordinary shares and pre-funded warrants. This initiative aims to enhance funding for its late-stage clinical developments focused on cardiovascular disease therapies. The offering, subject to market conditions, could potentially include an additional $45 million upon underwriters' discretion. The company's strategy reflects its commitment to developing effective LDL-C lowering treatments for patients with unmet medical needs.
Read more →NAMS▼ -15.5%on this news
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors a
NewAmsterdam Pharma announced positive topline data from its Phase 3 TANDEM clinical trial for the fixed-dose combination of obicetrapib and ezetimibe. The trial met all primary endpoints, showing a significant reduction in LDL-C levels compared to placebo. Over 70% of patients achieved LDL-C levels below recommended benchmarks after 84 days of treatment. The outcomes are expected to support global regulatory filings for this combination therapy, which aims to address unmet needs in patients with cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 Met primary end
NewAmsterdam Pharma presented additional data from its Phase 3 BROOKLYN clinical trial for obicetrapib at the AHA Scientific Sessions 2024. The trial demonstrated a significant reduction in LDL-C compared to placebo, achieving a mean reduction of 36.3% at day 84 and 41.5% at day 365. Additionally, the drug was well-tolerated, with safety results similar to those of the placebo group. The results are expected to provide new treatment options for patients with heterozygous familial hypercholesterolemia who have not responded adequately to existing therapies.
Read more →NAMS▲ +13.7%on this news· ran to +28% by day 3
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results – Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – &#
NewAmsterdam Pharma has reported a robust third quarter, highlighting the accelerated enrollment in its pivotal Phase 3 TANDEM trial, with topline data expected in Q4 2024. The company also anticipates reporting data from the BROADWAY trial in the same timeframe. Financially, NewAmsterdam boasts a solid cash position of $422.7 million as of September 30, 2024, which is projected to support their ongoing clinical trials and strategic goals. The overall outlook remains positive as the firm continues to address unmet needs in cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
NewAmsterdam Pharma Company N.V. announced its participation in upcoming conferences where it will present pivotal data from the Phase 3 BROOKLYN study on obicetrapib, an oral CETP inhibitor for patients with Heterozygous Familial Hypercholesterolemia. The American Heart Association's Scientific Sessions will feature this late-breaking presentation. Additionally, company leaders will engage in a fireside chat at the Jefferies London Healthcare Conference. The data presented aims to showcase the efficacy and safety of obicetrapib in addressing elevated LDL-C levels in patients at risk of cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NewAmsterdam Pharma Company N.V. announced its participation in two upcoming investor conferences in September 2024, aiming to enhance engagement with investors. The Morgan Stanley 22nd Annual Global Healthcare Conference will feature a fireside chat with CFO Ian Somaiya, while the Cantor Global Healthcare Conference will include CEO Michael Davidson and CFO Somaiya in a discussion. The company, known for developing non-statin therapies for cardiovascular disease, aims to address significant unmet needs in LDL cholesterol management.
Read more →NAMSNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results -- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved prim
NewAmsterdam Pharma has announced positive topline results from its pivotal Phase 3 BROOKLYN trial of obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH), meeting its primary endpoint of reducing LDL-C levels compared to placebo. The company's financial results for the second quarter indicate strong cash reserves of $430.7 million and an increase in revenue. Upcoming milestones include reporting topline data from the BROADWAY and TANDEM trials in late 2024 and early 2025, respectively. Additionally, NewAmsterdam has extended US patent protection for obicetrapib until 2043, reinforcing its market position.
Read more →NAMS▼ -8.5%on this news
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia Achieved primary endpoint of LS mean red
NewAmsterdam Pharma announced positive topline results from its Phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia. The trial met its primary endpoint with a significant reduction in LDL-C levels at both day 84 and day 365. Obicetrapib showed a 36.3% reduction at day 84 and a 41.5% reduction at day 365 compared to placebo, with generally favorable safety results. The data suggest that obicetrapib may offer additional LDL-C lowering options for patients who do not adequately respond to existing therapies.
Read more →NAMSNewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
NewAmsterdam Pharma is scheduled to announce topline data from its Phase 3 BROOKLYN clinical trial on July 29, 2024. The trial evaluates obicetrapib, an oral therapy targeting patients with heterozygous familial hypercholesterolemia, a condition associated with elevated LDL cholesterol. The company's focus is on providing effective LDL-lowering solutions for individuals who have not responded well to existing therapies. A live webcast and conference call will be held to discuss the trial results, emphasizing NewAmsterdam's commitment to improving patient care in cardiovascular diseases.
Read more →NAMSNewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma has appointed Mark C. McKenna and Wouter Joustra as temporary non-executive directors of its Board. This move comes as the company anticipates pivotal Phase 3 data readouts for its LDL-lowering therapies. The new appointees bring significant industry experience that may enhance the company's strategic direction. Additionally, the company announced the departure of Sander Slootweg from its Board, effective July 16, 2024.
Read more →NAMSNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
NewAmsterdam Pharma has successfully completed patient enrollment in its pivotal Phase 3 TANDEM trial evaluating the fixed-dose combination of obicetrapib and ezetimibe for patients with Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. With 407 patients enrolled, the trial aims to assess the efficacy of this combination in reducing LDL-C levels compared to standard therapies. NewAmsterdam anticipates sharing topline data from the trial in the first quarter of 2025, reflecting ongoing efforts to deliver innovative solutions for patients inadequately managed on existing therapies.
Read more →NAMSNewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office New patent extends patent term for obicetrapib until July 2043 Naarden, the Netherla
NewAmsterdam Pharma announced the issuance of a new composition of matter patent for obicetrapib by the USPTO, extending its patent protection until July 2043. This patent underlies the company's strategy to maintain exclusivity as it continues multiple Phase 3 trials assessing obicetrapib's efficacy and safety as an LDL-lowering therapy. The company highlighted the ongoing need for effective treatments for cardiovascular disease, as existing therapies are often inadequate or poorly tolerated. The new patent represents a significant milestone in NewAmsterdam's efforts to meet this healthcare need.
Read more →NAMSNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma Company N.V. has announced its participation in two upcoming investor conferences in June 2024. CEO Michael Davidson and CFO Ian Somaiya will present at the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. The presentations aim to provide insights into the company's developments in oral, non-statin therapies for patients at risk of cardiovascular disease. Live webcasts of the events will be available on the company's website.
Read more →NAMSNewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma announced it will present new clinical and preclinical data on obicetrapib at upcoming medical meetings, including the EAS 92nd Congress and the NLA 2024 Scientific Sessions. These presentations will showcase obicetrapib's impact on key lipid biomarkers and its potential as a safe oral therapy for hypercholesterolemia. The company is also on track to report topline data from their important Phase 3 trials, BROOKLYN and BROADWAY, set for 2024. NewAmsterdam seeks to fulfill the demand for effective LDL-lowering therapies in patients with cardiovascular disease.
Read more →NAMSNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in
NewAmsterdam Pharma recently provided a corporate update along with its financial results for the first quarter of 2024. The company reported enrollment of over 9,500 patients in its Phase 3 PREVAIL cardiovascular outcomes trial and is on track to deliver topline data from two additional pivotal trials, BROOKLYN and BROADWAY, later this year. Financially, NewAmsterdam ended the quarter with $481.1 million in cash, although it saw a significant drop in revenue compared to the previous year, emphasizing the need for successful trial outcomes to drive future revenue.
Read more →NAMSNewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma announced it will host an R&D Day on May 16, 2024, featuring key opinion leaders in cardiovascular disease. The event will focus on the clinical development of obicetrapib, a novel CETP inhibitor aimed at improving LDL cholesterol management for CVD patients. The company has shown promising results in its Phase 2 trials and is currently conducting pivotal Phase 3 trials with significant enrollment milestones reached recently.
Read more →NAMS▼ -9.6%on this news
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer NAARDEN, the Netherlands and MIAMI
NewAmsterdam Pharma has appointed Juliette Audet as Chief Business Officer effective April 1, 2024. Audet, who has been an advisor since 2020, brings over a decade of experience in the biopharmaceutical sector. She aims to aid NewAmsterdam in its transition to a commercial organization while supporting the development of its obicetrapib therapy, which targets patients at risk of cardiovascular disease. The company anticipates significant clinical milestone outcomes this year.
Read more →NAMS()*+,-.%/0&%&(121.'(%-2))('13'(%1.141&2('55&01'%&))6'01-&%').3.121.'('52('55&01'74*62(* %&340.1.&%6('0%-2))1-&0&7&2(*%2)&'5%&340.1.&%.(2(*%121&%'0840.%9.31.'(%.( :-.3-%43-'55&06%').3.121.'('0%2)& :'4)97&4()2 :54)+ ; = ?
The article appears to contain a series of garbled symbols and nonsensical text without any coherent information regarding the news for NAMS. There are no discernible updates or relevant content that can be gathered or summarized. The lack of meaningful content makes it impossible to derive any additional insights or information from the material provided.
Read more →NAMSNewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 Pla
NewAmsterdam Pharma has reported full year financial results for 2023, highlighting significant advancements in its clinical trials for obicetrapib, a CETP inhibitor for lowering LDL cholesterol. The company remains on track to provide topline data from its Phase 3 BROOKLYN and BROADWAY trials in the latter half of 2024. Additionally, they plan to initiate the TANDEM trial in early 2024 and expect to complete enrollment in the PREVAIL trial shortly. NewAmsterdam also noted a successful public offering that strengthened its financial position with a pro forma cash balance of $500 million, setting the stage for future growth and development.
Read more →NAMSNewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma has announced the commencement of a public offering of its ordinary shares and pre-funded warrants. The offering aims to secure funds for the company's late-stage development of oral, non-statin therapies for patients at risk of cardiovascular disease. The company is confident in addressing unmet needs within the sector, although the completion and terms of the offering remain contingent on market conditions. Their clinical program continues to focus on investigational therapies that could enhance patient care in this space.
Read more →NAMS▲ +8.2%on this news· ran to +23% by day 3
January 2024 Disclaimer This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or t
NewAmsterdam Pharma Company N.V. presents forward-looking statements regarding their product candidate obicetrapib, which is in multiple Phase 3 trials for hypercholesterolemia. The company anticipates significant market opportunities in managing LDL cholesterol levels, with pivotal data readouts expected from 2024 to 2026. However, the company acknowledges various risks and uncertainties, including regulatory approvals and competition. Additionally, there are cautions that actual outcomes could significantly differ from predictions made in the presentation.
Read more →NAMSNewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors Naarden , the Netherlands and Miami, USA
NewAmsterdam Pharma has appointed William H. Lewis as the new Chair of its Board of Directors, succeeding Sander Slootweg. Lewis, a seasoned executive with over 30 years of experience in the pharmaceutical and finance sectors, is expected to guide the company through its next growth phase as it advances its CETP inhibitor, obicetrapib. NewAmsterdam's clinical efforts aim to provide a novel oral, low-dose option for cardiovascular disease patients who do not adequately respond to current treatments. The company is conducting two Phase 3 trials for obicetrapib, with multiple data readouts anticipated in 2024.
Read more →NAMSNewAmsterdam Pharma Announces 2024 Strategic Priorities Positioned for three Phase 3 trial readouts over the next 18 months Topline data expected from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and BROADWAY trial in ASCVD
NewAmsterdam Pharma has outlined its strategic priorities for 2024, anticipating significant milestones with three Phase 3 trial readouts scheduled over the next 18 months. The company expects topline data from the BROOKLYN trial in HeFH in Q3 2024 and the BROADWAY trial in ASCVD in Q4 2024. Additionally, NewAmsterdam plans to initiate a pivotal Phase 3 trial, TANDEM, in early 2024, with focus on its investigational treatment, obicetrapib. The company's positive Phase 2 results bolster expectations for advancements in LDL-C lowering therapies aimed at high-risk cardiovascular patients.
Read more →NAMS▼ -6.9%on this news
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2
NewAmsterdam Pharma provided a corporate update revealing the completion of enrollment in their pivotal BROADWAY and BROOKLYN Phase 3 trials, with topline data expected in the second half of 2024. The company announced promising initial data from a Phase 2a trial of obicetrapib for Alzheimer's patients with the ApoE4 mutation, indicating potential improvements in brain cholesterol metabolism. Additionally, leadership changes with the appointments of BJ Jones as Chief Commercial Officer and Ian Somaiya as Chief Financial Officer aim to bolster the company's strategic direction for future product launches.
Read more →NAMS▼ -10.1%on this news
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma has appointed Ian Somaiya as their new Chief Financial Officer. Somaiya brings over twenty-five years of experience in the biopharmaceutical industry, with a strong background as a healthcare executive and financial leader. His expertise will be crucial as the company focuses on the clinical development of obicetrapib, a treatment aimed at lowering LDL cholesterol. The company is optimistic about achieving pivotal clinical trial results in the near future, enhancing their commitment to patients with cardiovascular disease.
Read more →NAMSSeptember 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or
NewAmsterdam Pharma Company N.V. has presented forward-looking statements regarding its product candidate, obicetrapib, designed to address unmet needs in hypercholesterolemia. The company's milestones include significant LDL-lowering effects observed in clinical trials. However, inherent uncertainties remain regarding clinical trial outcomes and market conditions. Investors are cautioned that actual results may differ from the company's expectations based on various risks and market dynamics.
Read more →NAMSNewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer s Disease Who Carry an ApoE4 Mutation Observed reductions of 11% and 12% in 24- and 27-hydro
NewAmsterdam Pharma has announced initial results from a Phase 2a clinical trial evaluating obicetrapib in early Alzheimer’s disease patients with the ApoE4 mutation. The trial indicated an 11% and 12% reduction in key cholesterol metabolites in cerebrospinal fluid and an 8% increase in a significant Alzheimer's biomarker, respectively, suggesting improved cognitive function. The drug was well-tolerated among participants, with no serious adverse events reported. These findings may enhance treatment options for patients with limited alternatives in managing Alzheimer’s disease.
Read more →NAMSNew Insights on CETP Inhibition from Genetic Research and Clinical Trials John J.P. Kastelein, MD PhD FESC Emeritus Professor of Medicine Department of Vascular Medicine Academic Medical Center (AMC) of the University of
Recent research led by Dr. John J.P. Kastelein presents new insights into CETP inhibition and its potential benefits for cardiovascular health. Genetic studies indicate that individuals with certain CETP gene variants have a significantly reduced risk of cardiovascular events due to lower LDL-C levels. Despite previous failures of CETP inhibitors like Torcetrapib and Dalcetrapib, the findings suggest a need for further investigation into CETP inhibitors, as Anacetrapib showed promising long-term benefits in MACE reduction. Additionally, there is emerging evidence linking lower CETP activity to possible advantages in neurodegenerative diseases.
Read more →NAMSNewAmsterdam Pharma Announces Appointment of William BJ Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma has appointed William BJ Jones as its Chief Commercial Officer effective August 14, 2023. With over 30 years of experience, Jones will lead commercial functions as the company advances its pivotal Phase 3 development of obicetrapib, an oral CETP inhibitor targeting cardiovascular disease. His expertise in mass market product launches will be crucial as NewAmsterdam aims to address unmet needs in lipid management for high-risk patients. The appointment reflects the company's commitment to building a robust commercial organization in preparation for potential product approval.
Read more →NAMSNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the
NewAmsterdam Pharma reported significant achievements in its recent corporate update, including the successful completion of multiple Phase 2 trials for obicetrapib, which demonstrated substantial LDL-C reductions. The company closed an upsized $182 million secondary offering, expanding its investor base. It has also completed patient enrollment in the BROADWAY Phase 3 clinical trial and exceeded targets, with topline data expected in the second half of 2024. The developments reinforce NewAmsterdam's objective to provide a powerful LDL-lowering therapy for patients at high risk of cardiovascular disease.
Read more →NAMSCONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (UNAUDITED) For the six months ended June 30, Note 2023 2022 (In thousands of Euro, except per share amounts) Revenue 3 9,562 93,500 Research and development expenses 4
NewAmsterdam Pharma Company N.V. reported a significant operating loss of €75,102 for the six months ending June 30, 2023, in stark contrast to a profit of €54,513 for the same period in 2022. Revenue saw a drastic decline to €9,562, down from €93,500 a year prior. The total comprehensive loss stood at €83,981, compared to a profit of €54,513 in the previous year, highlighting severe financial challenges. The company's accumulated losses nearly doubled to €194,463, reflecting deteriorating financial health.
Read more →NAMSNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Dis
NewAmsterdam Pharma has successfully completed enrollment in the pivotal Phase 3 BROADWAY clinical trial for its investigational drug obicetrapib. The trial, aimed at patients with heterozygous familial hypercholesterolemia and/or established atherosclerotic cardiovascular disease, exceeded its target enrollment of 2,400 participants, with over 2,500 expected to be randomized. The company anticipates reporting topline results in the second half of 2024, supporting its commitment to addressing LDL-C management in high-risk cardiovascular patients.
Read more →NAMSOur Business Overview NewAmsterdam Pharma Company N.V. ( we, us, our or the Company ) is a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular diseas
NewAmsterdam Pharma is advancing its lead candidate, obicetrapib, a next-generation oral CETP inhibitor aimed at high-risk cardiovascular patients with inadequately managed LDL levels. The company is currently conducting several clinical trials, with promising results indicating significant LDL-C reductions when combined with ezetimibe. NewAmsterdam also plans to complete pivotal trials, including BROADWAY and BROOKLYN, with data expected in late 2024. The partnership with Menarini for commercialization in Europe further strengthens its market position.
Read more →NAMSNewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 Met Primary Endpoint wit
NewAmsterdam Pharma announced encouraging findings from its Phase 2 ROSE2 trial evaluating obicetrapib in combination with ezetimibe alongside high-intensity statin therapy. The trial demonstrated significant reductions in LDL cholesterol, with 87.1% of patients reaching the LDL-C target below 55 mg/dL. The drug combination showed a favorable safety profile, leading the company to plan for a Phase 3 trial set to begin in the first quarter of 2024. These results present promising insights for potential cardiovascular disease treatments.
Read more →NAMSCONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of NewAmsterdam Pharma Company N.V. (the Company ) to be held on
NewAmsterdam Pharma Company N.V. has issued a convening notice for its annual general meeting (AGM) scheduled for June 20, 2023. The agenda includes proposals for adopting annual accounts for the fiscal year 2022 and appointing Deloitte as the external auditor for the 2023 fiscal year. Shareholders and beneficial owners are required to follow specific procedures to attend and vote at the meeting. Notably, the company does not plan to pay cash dividends in the foreseeable future.
Read more →NAMSNewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023 NewAmsterdam to review data on webcast conference call on
NewAmsterdam Pharma Company N.V. is set to present full data from its ROSE2 trial at the National Lipid Association Scientific Sessions 2023. The late-breaking presentation will detail the efficacy of obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy. The company anticipates advancing to a definitive bioequivalence trial and a Phase 3 safety trial later this year. They aim to improve treatment options for cardiometabolic diseases, highlighting their innovative approach to LDL-C reduction in patients at high risk for cardiovascular diseases.
Read more →NAMSNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights Completed enrollment in BROOKLYN Phase 3 clinical trial evaluating obicetrapib in patients with heterozygous familial hyperchol
NewAmsterdam Pharma has completed enrollment ahead of schedule in its BROOKLYN Phase 3 clinical trial for obicetrapib, targeting patients with heterozygous familial hypercholesterolemia. The company expects topline results by the second half of 2024 and plans to present full data from the Phase 2 ROSE2 trial in June 2023. The enrollment levels in ongoing clinical trials like BROADWAY and PREVAIL are strong, reflecting a significant need for viable oral therapies in cardiometabolic diseases. Upcoming data releases from various Phase 2 trials are anticipated later in 2023.
Read more →NAMS▲ +9.5%on this news
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia Enrollment Completed Several Months Ahead of Schedule
NewAmsterdam Pharma has announced the completion of patient enrollment in its pivotal Phase 3 BROOKLYN clinical trial, which evaluates obicetrapib for treating adult patients with heterozygous familial hypercholesterolemia (HeFH). The enrollment was completed several months ahead of schedule, reflecting an unmet medical need for effective LDL-C treatment. The trial involved 354 patients across ten countries and will assess the impact of obicetrapib on LDL-C levels while also evaluating its safety profile. Topline results are anticipated in the second half of 2024.
Read more →NAMSNewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma has appointed Janneke van der Kamp to its Board of Directors, bringing over two decades of pharmaceutical experience, particularly in cardiovascular disease. The company is currently focused on advancing its clinical trials for obicetrapib, an oral therapy designed to lower LDL-C levels in patients at high risk for cardiovascular diseases. Janneke van der Kamp expressed enthusiasm about her role and the potential of obicetrapib to address unmet medical needs. The ongoing efforts reflect NewAmsterdam's commitment to improving patient outcomes in metabolic diseases.
Read more →NAMSNewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier He
NewAmsterdam Pharma (Nasdaq: NAMS) announced its full year 2022 financial results and corporate updates, marking 2022 as a transformative year. The company completed a business combination with FLAC and secured $235 million through a PIPE financing, ensuring operational funding through 2026. They reported positive topline data from their ROSE2 Phase 2 trial of obicetrapib and initiated a dose-finding study in Japan. The company is progressing with three pivotal Phase 3 trials, solidifying its commitment to developing innovative LDL-C lowering therapies for high-risk cardiovascular disease patients.
Read more →NAMSMarch 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or the
NewAmsterdam Pharma Company N.V. has issued a disclaimer stating that its presentation is for informational purposes only and does not constitute any offers or solicitations regarding securities. The company provided forward-looking statements about its product candidate, obicetrapib, highlighting potential markets and development milestones. However, it cautions that various risks and uncertainties may impact actual results, and that reliance on these statements should be avoided. The potential for future success hinges on numerous factors, including regulatory approvals and market conditions.
Read more →NAMSFebruary 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or
NewAmsterdam Pharma Company N.V. has provided a presentation outlining its development of oral obicetrapib, aiming to address unmet needs in hypercholesterolemia and cardiometabolic diseases. The company highlights achievements such as significant LDL-lowering efficacy observed in clinical trials and strong leadership support. However, it also warns about various risks and uncertainties that may affect the success and approval of its product candidate. The forward-looking statements in the presentation are not guarantees of future performance, and actual results may differ.
Read more →NAMSNewAmsterdam Pharma Appoints John W. Smither to its Board of Directors Naarden, the Netherlands and Miami, USA
NewAmsterdam Pharma has appointed John W. Smither as an independent director and chair of its Audit Committee. Smither brings valuable experience from previous roles in biotherapeutics and has expressed enthusiasm about joining the board at a pivotal time for the company. NewAmsterdam is currently advancing the clinical development of its oral therapy obicetrapib for cardiometabolic diseases and is preparing for potential commercialization in Europe. The company has recently completed a significant business combination, enhancing its financial standing to support ongoing clinical trials.
Read more →NAMSNewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy Achieved primary endpoint with statistically significa
NewAmsterdam Pharma announced positive topline results from the ROSE2 Phase 2 trial, where their drug obicetrapib, in combination with ezetimibe, achieved a significant reduction in LDL cholesterol levels. The trial demonstrated a 59% reduction in LDL-C for the combination group compared to 6% in the placebo group, indicating the efficacy of this treatment approach. The company plans to advance to a fixed-dose combination tablet for further testing in Phase 3 trials. Safety profiles were favorable, showing tolerability similar to placebo.
Read more →NAMSJanuary 2023 Disclaimer This presentation (together with oral statements made in connection herewith, this "Presentation") is for informational purposes only. This Presentation shall not constitute an offer to sell, or t
NewAmsterdam Pharma Company N.V. has provided a disclaimer regarding its presentation, emphasizing that it is for informational purposes only and does not constitute an offer to sell securities. The company outlines its development of oral obicetrapib to address hypercholesterolemia and other cardiometabolic diseases, detailing positive clinical trial results and key milestones. However, the presentation also highlights various risks and uncertainties related to regulatory approval processes and market conditions that could affect the company's future performance.
Read more →NAMS▲ +5.6%on this news
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer Naarden, the Netherlands and Miami, USA
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer Naarden, the Netherlands and Miami, USA; December 19, 2022 NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS or NewAmsterdam or the Company ), a clinical-stage company focused on the research and developm
Read more →NAMSNewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy f
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients Business com
Read more →Competitive Position
How NAMS ranks across every disease it competes inCompetitive Position is a premium feature
See how NAMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial